Southeastern Asset Management Inc. TN Has $101.34 Million Stock Position in Bio-Rad Laboratories, Inc. (NYSE:BIO)

Southeastern Asset Management Inc. TN reduced its position in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO - Free Report) by 3.1% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 308,469 shares of the medical research company's stock after selling 9,867 shares during the period. Bio-Rad Laboratories accounts for about 4.8% of Southeastern Asset Management Inc. TN's investment portfolio, making the stock its 8th largest position. Southeastern Asset Management Inc. TN owned about 1.10% of Bio-Rad Laboratories worth $101,335,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also modified their holdings of the company. Venturi Wealth Management LLC raised its stake in Bio-Rad Laboratories by 2,175.0% during the fourth quarter. Venturi Wealth Management LLC now owns 91 shares of the medical research company's stock worth $30,000 after purchasing an additional 87 shares during the period. GeoWealth Management LLC grew its holdings in shares of Bio-Rad Laboratories by 342.9% during the 4th quarter. GeoWealth Management LLC now owns 93 shares of the medical research company's stock worth $31,000 after purchasing an additional 72 shares during the period. Picton Mahoney Asset Management increased its position in Bio-Rad Laboratories by 55.6% during the 4th quarter. Picton Mahoney Asset Management now owns 98 shares of the medical research company's stock worth $32,000 after purchasing an additional 35 shares in the last quarter. Asset Planning Inc purchased a new position in Bio-Rad Laboratories in the fourth quarter valued at approximately $33,000. Finally, UMB Bank n.a. lifted its position in Bio-Rad Laboratories by 41.6% during the fourth quarter. UMB Bank n.a. now owns 109 shares of the medical research company's stock valued at $36,000 after buying an additional 32 shares in the last quarter. 65.24% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several research firms have recently issued reports on BIO. Citigroup dropped their price objective on shares of Bio-Rad Laboratories from $400.00 to $350.00 and set a "buy" rating for the company in a research report on Friday, May 2nd. StockNews.com downgraded Bio-Rad Laboratories from a "buy" rating to a "hold" rating in a report on Monday, February 17th. Royal Bank of Canada reduced their price objective on Bio-Rad Laboratories from $409.00 to $392.00 and set an "outperform" rating on the stock in a research note on Friday, May 2nd. UBS Group decreased their target price on Bio-Rad Laboratories from $355.00 to $310.00 and set a "buy" rating for the company in a research report on Friday, May 2nd. Finally, Wells Fargo & Company dropped their target price on Bio-Rad Laboratories from $320.00 to $270.00 and set an "equal weight" rating on the stock in a report on Thursday, April 17th. Three investment analysts have rated the stock with a hold rating and three have given a buy rating to the company. According to MarketBeat.com, Bio-Rad Laboratories currently has a consensus rating of "Moderate Buy" and an average price target of $327.40.

Bio-Rad Laboratories Stock Down 5.4%

NYSE BIO traded down $13.28 during trading hours on Wednesday, reaching $233.77. 62,463 shares of the company traded hands, compared to its average volume of 315,903. The stock has a market capitalization of $6.36 billion, a PE ratio of -3.59 and a beta of 1.00. The company has a current ratio of 6.48, a quick ratio of 4.85 and a debt-to-equity ratio of 0.18. Bio-Rad Laboratories, Inc. has a 12 month low of $215.38 and a 12 month high of $387.99. The company has a 50 day moving average of $243.42 and a two-hundred day moving average of $296.91.

Bio-Rad Laboratories (NYSE:BIO - Get Free Report) last announced its quarterly earnings data on Thursday, May 1st. The medical research company reported $2.54 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.73 by $0.81. The firm had revenue of $585.40 million for the quarter, compared to analysts' expectations of $573.01 million. Bio-Rad Laboratories had a positive return on equity of 3.90% and a negative net margin of 71.86%. Bio-Rad Laboratories's revenue for the quarter was down 4.2% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $2.30 earnings per share. As a group, equities analysts expect that Bio-Rad Laboratories, Inc. will post 10.81 earnings per share for the current year.

Bio-Rad Laboratories Profile

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.